zilucoplan achiev stat primari secondari
endpoint earlier morn rarx announc posit top-lin data
pbo-control trial treatment gmg
dose higher dose cohort mg/kg sc daili demonstr
point reduct baselin pbo-correct qmg primari
endpoint dose cohort demonstr reduct
point pbo-correct mg-adl key secondari endpoint approv
endpoint base preced view data highli competit
in-lin potenti competitor put zilucoplan favor posit
across evolv landscap gmg rescu therapi ivig plex
requir patient pbo arm patient
lower dose mg/kg cohort zero patient higher dose
cohort support zilucoplan promis efficaci profil addit
drug well-toler profil consist pnh
studi compani engag fda discuss registr
design util mg/kg dose preliminarili expect data
today data highli de-risk tp
establish role complement gmg valid soliri approv
today highli competit data rais po program
rais tp highlight zilucoplan
deep-div see substanti market opportun well-pric
target agent zilucoplan expans opportun well beyond
current target market soliri current model global
opportun healthi uptak across uncontrol
moderate/sever gmg popul model gross price us
launch comp well manag guidanc ivig price
high gross us current
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
ra pharma clinical-stag biopharma use proprietari peptid
chemistri platform develop novel therapeut treatment
price dec rate outperform target price analyst martin auster
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
 weight higher peak penetr
gmg us theeu
 weight half peak penetr
gmg us eu
compani mention price
